MRSN

Mersana Therapeutics Inc

MRSN, USA

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

https://www.mersana.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MRSN
stock
MRSN

Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout Yahoo Finance

Read more →
MRSN
stock
MRSN

683 Capital Management LLC Boosts Stock Position in Mersana Therapeutics, Inc. $MRSN MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$33.2

Analyst Picks

Strong Buy

8

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-2.37

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

12.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.04 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-28.99 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 65.48% of the total shares of Mersana Therapeutics Inc

1.

Nextech Invest, Ltd.

(9.6718%)

since

2025/03/31

3.

Vanguard Group Inc

(6.7147%)

since

2025/03/31

4.

BlackRock Inc

(6.6734%)

since

2025/03/31

5.

Schonfeld Strategic Advisors LLC

(6.1026%)

since

2025/03/31

6.

AQR Capital Management LLC

(4.1227%)

since

2025/03/31

7.

Rock Springs Capital Management LP

(3.0574%)

since

2025/03/31

8.

Vanguard Total Stock Mkt Idx Inv

(2.7224%)

since

2025/07/31

9.

SILVERARC CAPITAL MANAGEMENT, LLC

(2.4754%)

since

2025/03/31

10.

State Street Corp

(2.087%)

since

2025/03/31

11.

Geode Capital Management, LLC

(1.9575%)

since

2025/03/31

12.

Vanguard Explorer Inv

(1.6085%)

since

2025/06/30

13.

Catalio Capital Management, LP

(1.3666%)

since

2025/03/31

14.

683 Capital Management LLC

(1.3225%)

since

2025/03/31

15.

Jacobs Levy Equity Management, Inc.

(1.0685%)

since

2025/03/31

16.

5AM Venture Management, LLC

(1.0459%)

since

2025/03/31

17.

Qube Research & Technologies

(0.9414%)

since

2025/03/31

18.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8396%)

since

2025/07/31

19.

Northern Trust Corp

(0.6931%)

since

2025/03/31

20.

Renaissance Technologies Corp

(0.6732%)

since

2025/03/31

21.

Deutsche Bank AG

(0.673%)

since

2025/03/31

22.

IEQ CAPITAL, LLC

(0.5667%)

since

2025/03/31

23.

Lion Point Capital, LP

(0.5162%)

since

2025/03/31

24.

iShares Biotechnology ETF

(0.4793%)

since

2025/08/31

25.

Vanguard VIF Small Co Gr

(0.3273%)

since

2025/06/30

26.

Extended Equity Market Fund K

(0.1675%)

since

2025/06/30

27.

Vanguard Market Neutral I

(0.0947%)

since

2025/06/30

28.

NT Ext Equity Mkt Idx Fd - L

(0.0848%)

since

2025/06/30

29.

Northern Trust Extended Eq Market Idx

(0.0848%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - NL

(0.0692%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0538%)

since

2025/06/30

32.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0452%)

since

2025/03/31

33.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0415%)

since

2024/12/31

34.

Russell 2500â„¢ Index Fund F

(0.0395%)

since

2025/06/30

35.

U.S. Equity Market Fund F

(0.0328%)

since

2025/06/30

36.

Russell 2000 Index Non-Lendable Fund E

(0.0326%)

since

2025/06/30

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0239%)

since

2025/06/30

38.

Extended Equity Market Fund M

(0.0211%)

since

2025/06/30

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0202%)

since

2024/12/31

40.

China Universal NASDAQ Bio-Tch ETF(QDII)

(0.0201%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.51

EPS Estimate

-0.14

EPS Difference

-1.37

Surprise Percent

-978.5714%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.